Safety, efficacy, and side effects of sodium fluorescein-aided resection of glioblastoma: a quasi-experimental study.

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL
Annals of Medicine and Surgery Pub Date : 2024-10-07 eCollection Date: 2024-11-01 DOI:10.1097/MS9.0000000000002633
Nazmin Ahmed, Md Nazrul Hossain, Raju Ahmed, Md Mahmud Abbasi, Mohammed A Azab, Morshad Alam, Nazia Nusrat Khan, Md Raad Kazi, Nusrat Ghafoor, Nawshin Siraj, Bipin Chaurasia
{"title":"Safety, efficacy, and side effects of sodium fluorescein-aided resection of glioblastoma: a quasi-experimental study.","authors":"Nazmin Ahmed, Md Nazrul Hossain, Raju Ahmed, Md Mahmud Abbasi, Mohammed A Azab, Morshad Alam, Nazia Nusrat Khan, Md Raad Kazi, Nusrat Ghafoor, Nawshin Siraj, Bipin Chaurasia","doi":"10.1097/MS9.0000000000002633","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of fluorescein sodium (FS) as a surgical adjunct in glioblastoma resection has shown promise in improving tumor visualization and resection outcomes. This study aimed to evaluate the safety, efficacy, and side effects of FS-aided resection in patients with glioblastoma.</p><p><strong>Methods: </strong>This is a prospective, single-center cohort study conducted at Ibrahim Cardiac Hospital and Research Institute from September 2021 to November 2023. Twelve patients with histologically confirmed glioblastoma underwent FS-guided resection. All participants received an intravenous dose of FS (5 mg/kg body weight) ~30 min before surgery. The study follows a quasi-experimental design, focusing on the outcomes of FS-aided surgery without a control group. Patients were selected based on specific inclusion and exclusion criteria, and all surgeries were performed by a single experienced neurosurgeon. The extent of tumor resection was classified as gross total resection (GTR), near-total resection (NTR), or partial resection (PR).</p><p><strong>Results: </strong>Gross total resection (GTR) was achieved in 66.6% of patients, near total resection (NTR) in 16.6%, and subtotal resection (STR) in 16.6%. No significant adverse effects were observed except for a single case of postoperative seizure, which was managed without long-term consequences. All patients showed normal liver and kidney function tests postoperatively. The low-dose FS protocol demonstrated both a high rate of GTR and a favorable safety profile, with only minor, transient side effects such as temporary yellow discoloration of the skin, sclera, and urine. No severe or long-term complications related to FS were observed during the follow-up period, which had a median duration of 13.4 months.</p><p><strong>Conclusion: </strong>FS appears to be a safe and effective aid in glioblastoma resection, achieving high rates of GTR with minimal side effects. The findings suggest that FS, particularly at a low dose, is a viable, cost-effective alternative to other fluorescent markers, especially in settings where resource constraints may limit the use of more expensive options like 5-ALA.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"86 11","pages":"6521-6530"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543223/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000002633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The use of fluorescein sodium (FS) as a surgical adjunct in glioblastoma resection has shown promise in improving tumor visualization and resection outcomes. This study aimed to evaluate the safety, efficacy, and side effects of FS-aided resection in patients with glioblastoma.

Methods: This is a prospective, single-center cohort study conducted at Ibrahim Cardiac Hospital and Research Institute from September 2021 to November 2023. Twelve patients with histologically confirmed glioblastoma underwent FS-guided resection. All participants received an intravenous dose of FS (5 mg/kg body weight) ~30 min before surgery. The study follows a quasi-experimental design, focusing on the outcomes of FS-aided surgery without a control group. Patients were selected based on specific inclusion and exclusion criteria, and all surgeries were performed by a single experienced neurosurgeon. The extent of tumor resection was classified as gross total resection (GTR), near-total resection (NTR), or partial resection (PR).

Results: Gross total resection (GTR) was achieved in 66.6% of patients, near total resection (NTR) in 16.6%, and subtotal resection (STR) in 16.6%. No significant adverse effects were observed except for a single case of postoperative seizure, which was managed without long-term consequences. All patients showed normal liver and kidney function tests postoperatively. The low-dose FS protocol demonstrated both a high rate of GTR and a favorable safety profile, with only minor, transient side effects such as temporary yellow discoloration of the skin, sclera, and urine. No severe or long-term complications related to FS were observed during the follow-up period, which had a median duration of 13.4 months.

Conclusion: FS appears to be a safe and effective aid in glioblastoma resection, achieving high rates of GTR with minimal side effects. The findings suggest that FS, particularly at a low dose, is a viable, cost-effective alternative to other fluorescent markers, especially in settings where resource constraints may limit the use of more expensive options like 5-ALA.

荧光素钠辅助胶质母细胞瘤切除术的安全性、有效性和副作用:一项准实验研究。
背景:在胶质母细胞瘤切除术中使用荧光素钠(FS)作为手术辅助用药有望改善肿瘤的可视化和切除效果。本研究旨在评估荧光素钠辅助胶质母细胞瘤切除术的安全性、有效性和副作用:这是一项前瞻性单中心队列研究,于 2021 年 9 月至 2023 年 11 月在易卜拉欣心脏病医院和研究所进行。12名组织学确诊的胶质母细胞瘤患者接受了FS引导下的切除术。所有参与者均在手术前 30 分钟静脉注射 FS(5 毫克/千克体重)。该研究采用准实验设计,重点研究FS辅助手术的结果,不设对照组。根据特定的纳入和排除标准选择患者,所有手术均由一名经验丰富的神经外科医生实施。肿瘤切除范围分为全切(GTR)、近全切(NTR)或部分切除(PR):结果:66.6%的患者实现了肿瘤全切(GTR),16.6%的患者实现了近全切(NTR),16.6%的患者实现了次全切(STR)。除一例术后癫痫发作外,未观察到明显的不良反应。所有患者术后肝肾功能检查均正常。低剂量 FS 方案显示了较高的 GTR 率和良好的安全性,仅有轻微的一过性副作用,如皮肤、巩膜和尿液暂时变黄。在中位持续时间为 13.4 个月的随访期间,没有观察到与 FS 相关的严重或长期并发症:结论:FS似乎是胶质母细胞瘤切除术中一种安全有效的辅助手段,可实现较高的GTR率,且副作用极小。研究结果表明,FS,尤其是低剂量的FS,是一种可行的、具有成本效益的荧光标记物替代品,尤其是在资源紧张可能会限制使用5-ALA等更昂贵的荧光标记物的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Medicine and Surgery
Annals of Medicine and Surgery MEDICINE, GENERAL & INTERNAL-
自引率
5.90%
发文量
1665
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信